Aust Mathias C, Reimers Kerstin, Repenning Claudia, Stahl Frank, Jahn Sabrina, Guggenheim Merlin, Schwaiger Nina, Gohritz Andreas, Vogt Peter M
Hannover, Germany; Zurich, Switzerland; and Graz, Austria From the Klinik für Plastische, Hand- und Wiederherstellungschirurgie, Medizinische Hochschule Hannover, the Department of Technical Chemistry, University of Hannover, the Klinik für Wiederherstellungschirurgie, Universitätsspital Zurich, and the Klinische Abteilung für Plastische, Rekonstruktive und Ästhetische Chirurgie, Universitätsklinik Graz.
Plast Reconstr Surg. 2008 Nov;122(5):1553-1563. doi: 10.1097/PRS.0b013e318188245e.
Photoaging is generally treated by ablative procedures that injure the epidermis and basal membrane and lead to fibrosis of the papillary dermis. Damaging the epidermis significantly can cause potential adverse effects such as dyspigmentation. It was recently shown in clinical trials that percutaneous collagen induction therapy is an alternative for safely treating wrinkles and scars and for smoothening the skin without the risk of dyspigmentation.
The purpose of this study was to increase current knowledge regarding whether percutaneous collagen induction therapy presents an effective means for skin rejuvenation without risk of dyspigmentation, as the authors' clinical data suggested. Fifty-six rats were assigned to three groups: group A (n = 24), percutaneous collagen induction therapy plus skin care; group B (n = 24), skin care; and group C (n = 8) controls. The authors evaluated the effect of percutaneous collagen induction therapy on the epidermis, melanocytes, and the pigmentation markers interleukin-10 and melanocyte-stimulating hormone.
Percutaneous collagen induction therapy left the epidermis intact without any damage to the stratum corneum, any other layers of the epidermis, or the basal membrane. No signs of dermabrasive reduction of epidermal thickness were evident 24 hours after the procedure. The number of melanocytes neither increased nor decreased in any of the groups. DNA microarray experiments demonstrated that interleukin-10 was increased in percutaneous collagen induction therapy-treated skin after 2 weeks. Concerning the MC1R (melanocyte-stimulating hormone) gene, gene expression microarray analysis indicated a faint down-regulation both 24 hours and 2 weeks after percutaneous collagen induction therapy.
Percutaneous collagen induction therapy offers a modality with which to rejuvenate and improve skin appearance and quality without risk of dyspigmentation.
光老化通常采用剥脱性治疗方法，这些方法会损伤表皮和基底膜，并导致乳头真皮纤维化。显著损伤表皮会引起诸如色素沉着异常等潜在不良反应。最近的临床试验表明，经皮胶原诱导疗法是一种安全治疗皱纹和疤痕以及使皮肤光滑的替代方法，且没有色素沉着异常的风险。
本研究的目的是，正如作者的临床数据所提示的那样，增加关于经皮胶原诱导疗法是否是一种有效且无色素沉着异常风险的皮肤年轻化手段的现有知识。56只大鼠被分为三组：A组（n = 24），经皮胶原诱导疗法加皮肤护理；B组（n = 24），皮肤护理；C组（n = 8）为对照组。作者评估了经皮胶原诱导疗法对表皮、黑素细胞以及色素沉着标记物白细胞介素 - 10和促黑素的影响。
经皮胶原诱导疗法使表皮保持完整，角质层、表皮的任何其他层或基底膜均未受到任何损伤。术后24小时没有明显的表皮厚度因磨皮而减少的迹象。任何一组中的黑素细胞数量均未增加或减少。DNA微阵列实验表明，2周后经皮胶原诱导疗法治疗的皮肤中白细胞介素 - 10增加。关于MC1R（促黑素）基因，基因表达微阵列分析表明，经皮胶原诱导疗法后24小时和2周均有轻微下调。
经皮胶原诱导疗法提供了一种使皮肤年轻化并改善皮肤外观和质量且无色素沉着异常风险的方式。
